// STATE LEGISLATION TRACKER

Texas HB 195: Relating to the regulation of the cultivation, processing, packaging, labeling, distribution, sale, testing, transportat

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Texas
Bill: HB 195
Session: 892
Filed: 2025-07-24
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Texas HB195 would add mifepristone and misoprostol to Schedule IV under the Texas Controlled Substances Act. Based on the title, subjects, status, and available bill text, it does not target peptides, compounding pharmacies, off-label peptide prescribing, telehealth peptide care, NP scope, naturopathic scope, or FDA 503A/503B compounding.

Key Points

No compounded peptides are named or directly restricted.
No change appears to FDA 503A or 503B peptide compounding rules.
No telehealth, NP, or naturopathic prescribing scope change is apparent.
Clinics using mifepristone or misoprostol would face controlled-substance handling rules.
Peptide users should treat this as abortion-drug policy, not peptide policy.

What to Watch For

Note Watch whether future amendments add other drugs beyond mifepristone and misoprostol.

Concern If enacted, affected clinicians may see more prescribing, storage, and dispensing compliance work.

Note This does not appear to change peptide access unless later language broadens the drug list.

Where the Bill Stands

The bill has been referred to the House State Affairs committee and has not passed a chamber.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws